The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy

BACKGROUND: This study shows the results of a regional pharmacovigilance program on Natalizumab therapy in relapsing-remitting multiple sclerosis (RR-MS) patients after 3 years of experience. MATERIAL/METHODS: The primary objectives of this study were to estimate the incidence of expected and unexpe...

Descripción completa

Detalles Bibliográficos
Autores principales: Giacoppo, Sabrina, Ruscica, Maria, Grimaldi, Luigi Maria, Bramanti, Placido, Mazzon, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592973/
https://www.ncbi.nlm.nih.gov/pubmed/28864818
http://dx.doi.org/10.12659/MSM.903301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592973/
https://www.ncbi.nlm.nih.gov/pubmed/28864818
http://dx.doi.org/10.12659/MSM.903301

Ejemplares similares